New cancer clinical trial: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, With Cetuximab in Subjects With Advanced Solid Cancers

Published on: January 25, 2019 at 12:00PM
Condition:   Neoplasms
Interventions:   Drug: CC-95251;   Drug: Cetuximab
Sponsor:   Celgene
Not yet recruiting
http://bit.ly/2S3uODd